A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
Sponsor: Novartis
A observational or N/A phase clinical study on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation, this trial is ongoing. The trial is conducted by Novartis and has accumulated 7 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.